Head-to-head evidence
ALIA-1758 vs AV-1959R
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
ALIA-1758
Developed by AbbVie
NCT06406348 · Phase 1 · completed
The trial was randomized and blinded against placebo, but it was conducted in healthy volunteers purely to check safety and dosing rather than cognitive or disease benefit, and no results have been posted yet.
AV-1959R
Developed by Nuravax, Inc.
NCT06831812 · Phase 1 · completed
The trial was randomized and blinded with a placebo comparator, but it enrolled only 16 people in total, with as few as two per placebo group, and it was designed to test safety and antibody response rather than a disease outcome. No serious adverse events occurred in any group, but the very small numbers mean the safety comparison cannot rule much out.
Next expected readout: June 2029 · NCT07827768 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALIA-1758's landscape · AV-1959R's landscape